secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2026-08-11T20:00:21+00:00
Accession:  0001213900-26-087756
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD Q2 2026 net income $164K, revenue $869K; explores strategic alternatives
--------------------------------------------------------------------------------

- Net income from continuing operations $164K vs $545K in Q2 2025; license revenue $869K vs $952K.
- Total operating expenses $1.7M, up 2.3% YoY on higher G&A and patent write-off.
- Cash and cash equivalents $9.2M as of June 30, 2026.
- Company continues evaluating strategic alternatives including merger, sale, or other transactions; no timetable set.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000121390026087756/0001213900-26-087756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000121390026087756/ea0298979-8k_therapeu.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-087756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer